'The Top Line': A closer look at European biotech investment in 2024

Published on March 22, 2024

This week on “The Top Line,” we explore the European biotech investment landscape. 

Fierce Biotech’s James Waldron sits down with Maina Bhaman, a Partner at Sofinnova Capital Strategy, who provides insights into how investors are approaching the European biotech sector. 

 

To learn more about the topics in this episode: 

 

To Listen to More Episodes from The Top Line

Check Out the Full List

Continue reading on website
Other news

Boundless Bio eyes $88M offering as spring biotech IPO market blooms

March 21, 2024
Boundless Bio’s announcement earlier this month of plans to go public was a sign that the biotech IPO window hadn’t slammed shut after a flurry of offerings at the start of the year.Now, the company has set out its IPO pricing ambitions at the more modest end of the year’s offerings. Boundless is expecting to sell 22.2 million shares priced between $15 and $17 per share, according to a March 21 Se

Novartis Canada's statement on CADTH draft recommendations for LEQVIO (inclisiran)

March 22, 2024
MONTRÉAL, March 21, 2024 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is deeply disappointed with the draft recommendations of the Canadian Drug Expert Committee (CDEC) issued by the Canadian Agency for Drugs and Technologies in Health (CADTH) for LEQVIO® (inclisiran). These draft recommendations advise to not reimburse LEQVIO for the treatment of hypercholesterolemia for both